CEOs of major medtechs Medtronic, BD, J&J/Ethicon, Edwards Lifesciences, Stryker and Olympus Corp. discuss how the pandemic has shaken up the industry and redefined their companies’ strategies from supply chain and digital uptake to ambulatory and at-home care.

The medtech sector’s drive to create a fairer health care system and a greener world will go on after the COVID pandemic, which has brought such issues into sharp relief. CEOs at leading companies discuss environmental, social and governance imperatives for their companies and the larger industry.

The company originally expected the first-in-human trial of the soft-tissue robotic surgery system to begin in late 2022 and reach the market by 2023, but the company now expects those trials to begin in 2024.

Virtual and in-person events are planned for Washington, DC, and Minneapolis, MN, during the trade group gathering.